Brooks Automation, Inc. (now Azenta, Inc.) — Form 10-Q Summary
Reporting period: Quarter and nine months ended June 30, 2014; fiscal year ended September 30. The filing is under the historical name Brooks Automation, Inc., although the request identifies the company as Azenta, Inc.
Business Context
The company provided automation and vacuum solutions primarily to semiconductor capital-equipment customers, along with global service offerings and life-science sample-management systems. Semiconductor-related shipments represented approximately 53% of consolidated revenue for the first nine months of fiscal 2014. The company reported three segments: Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems.
Granville-Phillips was sold to MKS Instruments on May 30, 2014, for $87.0 million in cash and is presented as a discontinued operation. Prior-period results were revised accordingly.
Financial Metrics
| Metric | Three months ended June 30, 2014 | Year-over-year change | Nine months ended June 30, 2014 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $117.4 million | 6% | $360.3 million | 16% |
| Gross profit | $40.7 million | 13% | $125.9 million | 32% |
| Gross margin | 34.7% | Up from 32.6% | 34.9% | Up from 30.6% |
| Operating income (loss) | $(5.9) million | Versus $2.1 million income | $(2.1) million | Versus $(15.5) million |
| Income (loss) from continuing operations | $(2.8) million | Versus $4.5 million income | $1.3 million | Versus $(9.0) million |
| Net income attributable to Brooks | $24.5 million | Versus $1.5 million | $31.1 million | Versus $(8.2) million |
| Diluted earnings per share | $0.36 | Versus $0.02 | $0.46 | Versus $(0.13) |
Reported net income was substantially affected by the $26.9 million after-tax gain from the Granville-Phillips divestiture. Continuing operations remained unprofitable for the quarter and operating expenses exceeded gross profit.
Cash Flow, Liquidity and Capital Structure
- Cash and cash equivalents were $115.5 million at June 30, 2014, up from $83.0 million at September 30, 2013.
- Cash, cash equivalents and marketable securities totaled $243.8 million, including $57.1 million of short-term and $71.1 million of long-term marketable securities.
- Operating cash flow was $40.3 million for the first nine months, compared with $29.6 million in the prior-year period.
- Investing activities provided $5.8 million, including $85.4 million of divestiture proceeds, offset by the DMS acquisition, the BioCision investment, marketable-security purchases and capital expenditures.
- Financing activities used $15.2 million, primarily for $16.1 million of dividends.
- The company had $8.4 million of capital-lease obligations, including $0.9 million due within twelve months. No conventional debt balance is reported in the provided balance sheet.
- Letters of credit totaled approximately $21.0 million and related primarily to customer advances and performance obligations.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased 6%, driven mainly by a 109% increase in Life Science Systems revenue; Product Solutions revenue declined 5% because of lower semiconductor capital-equipment demand.
- Nine-month revenue increased 16%, with Product Solutions up 15%, Global Services up 8%, and Life Science Systems up 35%.
- Gross margin improved materially because of material and warranty-cost reductions, higher fixed-cost absorption, improved services productivity, and lower acquisition-related inventory step-up charges.
- R&D increased to $13.5 million for the quarter and $38.5 million for the nine months, reflecting product-development investment and acquisition-related costs.
- SG&A increased to $30.0 million for the quarter and $84.8 million for the nine months. The increase included higher incentive and stock-based compensation, acquisition costs, and a $2.6 million impairment of a strategic-partner note receivable.
- Restructuring charges rose to $3.1 million for the quarter but declined to $4.6 million for the nine-month period from $6.0 million in the prior year. The charges related primarily to workforce reductions, facility and production consolidation, discontinued product lines, and the Polycold manufacturing transition.
- The company acquired DMS for approximately $33.9 million net of cash acquired. DMS contributed $1.0 million of quarterly revenue and a $1.8 million net loss, including acquisition-related charges.
- The company acquired a 22% interest in BioCision for $4.0 million and recorded a $0.1 million loss from the investment during the quarter and nine-month period.
Outlook, Risks and Unusual Items
Management stated that it believed available resources were adequate to fund planned working capital and capital expenditures for at least the next twelve months. No specific revenue or earnings guidance is provided in the filing.
- Results remain exposed to the cyclical and difficult-to-predict demand environment for semiconductor capital equipment.
- Life Science Systems quarterly gross margin declined to 35.5% from 42.2%, primarily because a large automated sample-management project generated $3.6 million of revenue at a 5.9% gross margin.
- The strategic-partner note receivable was reduced to an estimated fair value of approximately $1.0 million after the company subordinated its security interest and extended the maturity; the valuation depends on uncertain cash-flow projections and discount rates.
- Restructuring accruals of $4.0 million were expected to be paid within twelve months, and the remaining Polycold severance cost was expected to be recorded in the fourth quarter of fiscal 2014.
- The company had approximately $24.5 million of short-term intercompany advances exposed to foreign-exchange movements. A hypothetical 10% currency change would have affected net income by approximately $0.5 million.
- Approximately 30% of first-nine-month sales were in currencies other than the U.S. dollar. A 100-basis-point interest-rate change was estimated to affect annual interest income by approximately $2.0 million.
- The company maintained valuation allowances against certain deferred tax assets and reported ongoing tax audits. Unrecognized tax benefits could decline by $1.5 million to $2.6 million during the following twelve months.
- Management reported that disclosure controls and procedures were effective and that there were no material changes in internal control over financial reporting.
- Legal proceedings were described as ordinary-course matters without a currently expected material adverse effect, although outcomes remain uncertain.
Investor Verification Points
- Verify the effect of the Granville-Phillips sale on continuing revenue, earnings, cash, taxes and future segment comparability.
- Assess whether the improved consolidated gross margin is sustainable after removing divestiture effects and considering the low-margin Life Science Systems project.
- Review semiconductor-capital-equipment exposure and order trends, particularly the quarterly decline in Product Solutions revenue.
- Evaluate DMS integration, acquisition accounting, goodwill and intangible-asset amortization, including the preliminary nature of portions of the purchase-price allocation.
- Monitor the collectability and revised maturity of the impaired strategic-partner note receivable.
- Reconcile reported net income and cash flow by separating the divestiture gain, non-cash tax effects, stock compensation, impairment charges and restructuring costs.
- Confirm dividend policy, the subsequent $0.10-per-share dividend declared July 30, 2014, and the company’s ability to maintain dividends through a semiconductor downturn.